Skip to content
Triangle logo TriangleGet started
← Melanoma

HEALTH PROFESSIONAL · SOURCE READING

Cobimetinib

Source: Melanoma Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 2, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment of Unresectable Stage III, Stage IV, and Recurrent Melanoma / Treatment Options for Unresectable Stage III, Stage IV, and Recurrent Melanoma / Signal transduction inhibitors / MEK inhibitors

Cobimetinib is a small-molecule, selective MEK inhibitor that the FDA approved in 2015 for use in combination with the BRAF inhibitor vemurafenib. For more information, visit the Combination therapy with signal transduction inhibitors section.

Source links and citations

Preserved source evidence · Not medical advice